יתרות מזומנים למניה אחת Harvard Bioscience Inc. (HBIO)

Harvard Bioscience (HBIO) relies on stable government grants, which minimizes the impact of crises. The consistent production of high-margin cell analysis instruments confirms the development of R&D. The free liquidity per share visualizes this margin of safety, where the current status equals 1.05. Harvard Bioscience (HBIO) creates advanced microfluidic chips, accelerating pharmaceutical development without the use of animals.
פילוחי מדדים מקיפים ואנליטיקה עבור harvardbioscience.com (HBIO)

Analyzing the financial stability of Harvard Bioscience (HBIO) remains a priority for investors. This metric is calculated by dividing total liquid assets by the total number of shares outstanding. The cash per share trend on the GURU.Markets platform reflects the company's ability to fund the development of high-precision cell analysis systems. A stable cash balance ensures the uninterrupted supply of toxicology tools, confirming the business's solvency within the biomedical research sector.